Previous Article | Next Article ![]()
Journal of Bacteriology, March 2001, p. 2111-2116, Vol. 183, No. 6
Department of Microbiology and Molecular
Genetics, Harvard Medical School, Boston, Massachusetts 02115
Received 12 September 2000/Accepted 18 December 2000
Protective antigen (PA), a component of anthrax toxin, binds
receptors on mammalian cells and is activated by a cell surface protease. The resulting active fragment, PA63, forms
ring-shaped heptamers, binds the enzymic moieties of the toxin,
and translocates them to the cytosol. Of the four crystallographic
domains of PA, domain 1 has been implicated in binding the enzymic
moieties; domain 2 is involved in membrane insertion and
oligomerization; and domain 4 binds receptor. To determine the function
of domain 3, we developed a screen that allowed us to isolate random
mutations that cause defects in the activity of PA. We identified
several mutations in domain 3 that affect monomer-monomer interactions in the PA63 heptamer, indicating that this may be the
primary function of this domain.
Anthrax toxin, a major virulence
factor of Bacillus anthracis, consists of three proteins:
two enzymic proteins (edema factor [EF] and lethal factor [LF])
plus a third (protective antigen [PA]), which serves as the vehicle
for delivery of the enzymic moieties to the cytosol of mammalian cells
(10). EF is a calmodulin-dependent adenylate cyclase
(9), whereas LF is a zinc-dependent protease that cleaves
mitogen-activated protein kinase kinases 1, 2, and 3 (4, 17,
20). The combination of PA and EF causes edema as a gross
manifestation of its activity, but its primary function is probably to
protect the invading bacteria from destruction by professional
phagocytes. The combination of PA and LF selectively affects
macrophages, causing, at high concentrations, their death and the death
of animals (5).
PA binds to an unidentified receptor on the surface of mammalian cells,
where it is activated by furin or a furin-like protease (7,
16). Cleavage of PA leads to the release of an amino-terminal fragment (PA20) and to heptamerization of the remainder of
the protein (PA63) through monomer-monomer interactions on
the cell surface (15). PA20 has no further
role in the intoxication process. PA63 binds EF and LF, and
these complexes are internalized by endocytosis (5, 6).
The low pH environment of the endosome causes the PA63
heptamer to insert into the membrane, apparently by forming a
14-stranded transmembrane PA is a 735-amino-acid protein organized into four domains, as defined
by X-ray crystallography (18). Furin cleavage within domain 1 (amino acids 1 to 258) leads to the release of
PA20, which in turn exposes a surface on PA63
that may be involved in binding EF and LF. Domain 2 (amino acids 259 to
487) contains an unstructured loop (D2L2), which inserts into membranes
to form a cation-selective channel (2, 14), and the domain
also contributes to a binding interface between PA63
monomers. Domain 3 (amino acids 488 to 595) has no reported function,
but its location suggests that it could participate in any of various
functions, including oligomerization, binding the receptor, and/or
binding the enzymic moieties. Domain 4 (amino acids 596 to 735) has
been shown to bind the anthrax toxin receptor (11, 19).
In order to explore the role of domain 3 in the intoxication process,
we have combined random mutagenesis of this domain with a novel screen
for mutations that affect the overall delivery function of PA. We found
mutations in distinct regions, including within a loop of domain 3 (amino acids 510 to 518), that impair heptamerization of
PA63. These oligomerization-deficient mutants are also
defective in their ability to bind LFN (the amino-terminal PA-binding domain of LF), suggesting that oligomerization of
PA63 is required for LF or EF to bind
PA63.
Plasmid construction.
The plasmid pET22b-PA contains the
entire PA gene, except for the portion that encodes the signal sequence
(1). QuikChange mutagenesis was performed according to the
instructions of the manufacturer (Stratagene) to introduce
site-directed mutations. Oligonucleotides were obtained from Integrated
DNA Technologies. The oligonucleotide, GAGTGAAGTGGTACCGCAAATTCA,
and its complement were used to introduce a KpnI site
into the vector pET22b-PA to make pET22b-PAK. The
oligonucleotide, CATAGCAGTTGGGATCGATGAGTCAGTAG, and its
complement were used to introduce a ClaI site into the vector pET22b-PAK to make pET22b-PAKC.
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.6.2111-2116.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Involvement of Domain 3 in Oligomerization by
the Protective Antigen Moiety of Anthrax Toxin
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-barrel (1, 12, 18). Conversion of the heptameric prepore to a pore is accompanied by
translocation of the enzymic moieties from an endosomal to a cytosolic
environment (8).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Mutagenesis.
A 100-µl PCR mixture containing 1×
Taq DNA polymerase buffer, 1 ng of pET22b-PAKC
DNA/µl, 2.5 ng of GAGTGAAGTGGTACCGCAAATTCA DNA/µl, 2.5 ng of CTACTGACTCATCGATCCCAACTGCTATG DNA/µl, 100 µM deoxynucleoside triphosphate, 1µM
6-(2-deoxy-
-D-ribo- furanosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one triphosphate (dPTP)
(Amersham Life Science), and 0.05 U of Taq DNA polymerase (Stratagene)/µl was used to amplify a DNA fragment encoding domain 3 of PA. The mixture was initially incubated at 95°C for 45 s. A
cycle consisting of a 45-s incubation at 95°C, a 45-s incubation at
55°C, and a 40-s incubation at 72°C was then repeated 30 times. Five microliters of this first reaction mixture was used in a second
reaction mixture that lacked pET22b-PAKC DNA and dPTP
(incubation temperatures and times were the same as described above).
The product from the second reaction was purified using a QIAquick PCR
purification kit (Qiagen), cut with ClaI and
KpnI, and again purified using a QIAquick PCR purification
kit. This fragment was ligated into pET22b-PAKC, which had
been grown in the Escherichia coli strain SCS-110
(Stratagene), cut with ClaI and KpnI, and purified from an agarose gel using a QIAquick gel extraction kit (Qiagen).
Preparation of PA and LFN-DTA lysates. pET22b-PAKC vectors containing mutations introduced into PA (see above) were transformed into BL21 (DE3) cells (Stratagene) and spread on 1.5% agarose plates containing Luria broth (LB) and 50 µg of ampicillin/ml. The resulting colonies were used to inoculate 100 µl of LB containing 50 µg of ampicillin/ml in 96-well plates. The cultures were grown overnight, and then 100 µl of 50% glycerol was added to each well. Fifty microliters was then transferred into 100 µl of LB containing 50 µg of ampicillin/ml in a second 96-well plate. Cells were grown at 30°C with shaking. When the cells reached log phase, 20 µl of bacteriophage T7 lysate (supernatant of a T7 infection of log-phase XL1-blue E. coli cells, which was then diluted 10-fold with LB) was added. When the cells had lysed (approximately 3 h after infection), plates were centrifuged at 1,500 × g for 10 min to pellet the cellular debris.
LFN-DTA lysates were prepared by infecting a 30°C log-phase culture of BL21(DE3) cells containing the vector pET15b-LFN-DTA (13). When the cells had lysed, the culture was centrifuged to separate the cellular debris from the supernatant, which contained LFN-DTA.Screen for PA mutants. CHO-K1 cells (ATCC CCL-61) were grown in Ham's F-12 medium supplemented with 10% calf serum, 500 U of penicillin G/ml, and 500 U of streptomycin sulfate/ml. Twenty microliters of PA lysate and 10 or 2.5 µl of LFN-DTA lysate were added to confluent CHO-K1 cells in 100 µl of medium per well of a 96-well plate and incubated overnight. CHO-K1 cells were scored as dead if they were rounded.
Preparation of proteins. PA, PA63, LFN, and LFN-DTA were purified from E. coli as described previously (12, 21). Protein concentrations were determined using Bradford protein assay reagent (Bio-Rad).
Translocation assay. Translocation assays were performed essentially as described previously (21). Briefly, CHO-K1 cells were incubated on ice with trypsin-nicked PA for 1 h. The cells were washed twice with phosphate-buffered saline (PBS) and then incubated on ice with 35S-labeled LFN for 1 h. The cells were washed twice with PBS and exposed to MES-gluconate buffer (140 mM NaCl, 5 mM sodium gluconate, 20 mM 4-morpholineethanesulfonic acid) at pH 4.8 for 2 min. The cells were either lysed with lysis buffer (0.1 M NaCl, 20 mM NaH2PO4, 10 mM EDTA, 1% Triton X-100) or treated with 2 mg of pronase/ml at 37°C for 10 min. Cells that had been treated with pronase were centrifuged, resuspended in medium containing Mini Complete protease inhibitor (Boehringer Mannheim), centrifuged, and resuspended in lysis buffer. Radioactive content was determined by scintillation counting.
Rubidium release assay.
Confluent CHO-K1 cells in 24-well
plates were exposed overnight to medium containing 86Rb at
1 µCi/ml. Cells were incubated at 4°C for 30 min, washed with cold
PBS, and exposed to medium containing 2 × 10
8 M
trypsin-nicked PA for 1 h. The cells were washed twice with PBS
and exposed to 500 µl of MES-gluconate buffer at pH 4.8. After 30 min, 100 µl of buffer was removed. Radioactive content of the supernatant was determined by gamma radiation counting.
Protein synthesis inhibition assay. The protein synthesis inhibition assay was performed essentially as described previously (13). Various amounts of PA or mutant PA were incubated with CHO-K1 cells for 4 h at 37°C in the presence of LFN-DTA. The cells were washed with PBS and then incubated with leucine-deficient medium supplemented with 1 µCi of [3H]leucine/ml. The cells were incubated for 1 h at 37°C and then washed twice with cold PBS. The cells were incubated for 10 min at room temperature, first with 10% trichloroacetic acid and then with 0.2 M KOH. An equal volume of 0.1 M HCl was added, and the amount of tritiated protein was determined by scintillation counting.
Native gel electrophoresis. Trypsin-nicked PA, PA63, and LFN were mixed, as indicated, in 20 mM Tris-HCl (pH 8.0)-150 mM NaCl (in a volume of 8 µl) and incubated for approximately 10 min at room temperature. Two microliters of loading dye (bromophenol blue in 50% glycerol) was added to the mixtures, which were then loaded onto 4 to 20% acrylamide, Tris-glycine gels (BioWhittaker Molecular Applications). The running buffer was 25 mM Tris-base-192 mM glycine. The gels were stained with 0.05% Coomassie blue R-250-50% methanol-10% acetic acid and then destained with 10% acetic acid-10% methanol.
| |
RESULTS |
|---|
|
|
|---|
Preparation of mutant PA lysates. We used the nucleotide analog dPTP in PCRs to introduce mutations in the DNA encoding domain 3 of PA. This procedure causes A-to-G, T-to-C, G-to-A, and C-to-T transitions (22). A concentration of dPTP was used that resulted in an error rate of approximately one mutation per PCR product (data not shown). At this level of mutagenesis by dPTP, we estimated that only 2% of the mutations obtained would be nonsense mutations. To facilitate cloning of mutagenized domain 3 DNA, we introduced into the PA gene a KpnI site (which mutated amino acid 481 from Leu to Val) and a ClaI site (which mutated amino acid 607 from Ala to Ile). A population of constructs containing mutagenized domain 3 DNA was transformed into BL21(DE3) cells. Colonies from this transformation were used to inoculate LB-ampicillin in 96-well plates, and after overnight growth, the cells were used to inoculate a second 96-well plate. When the cells reached log phase, they were infected with bacteriophage T7, thereby lysing them and releasing PA from the periplasm into the medium. Lysates were centrifuged to separate the cellular debris from the supernatant.
Screen for defective PA mutants. CHO-K1 cells in 96-well plates were incubated overnight with 20 µl of (mutant) PA lysate and 10 µl of LFN-DTA lysate (LFN-DTA consists of the amino-terminal, PA-binding domain of LF fused to the catalytic domain of diphtheria toxin, which inhibits protein synthesis by catalyzing the ADP ribosylation of elongation factor-2). The cells were observed under a microscope and scored as dead if they had rounded. Killing of the CHO-K1 cells depended on the presence of both PA lysate and LFN-DTA lysate (data not shown).
Of the 93 lysates screened, 45 killed CHO-K1 cells and 48 did not. Western blotting revealed that 10 of the 48 lysates contained full-length PA, and we sequenced seven of the 10 corresponding clones (Table 1 and Fig. 1). Three did not have PCR-induced mutations (these clones expressed reduced levels of PA for reasons that are unclear), three contained single missense mutations, and one had two missense mutations.
|
|
Native gel electrophoresis of PA mutants and LFN.
Electron microscopy has revealed that, in solution, LFN can
convert trypsin-nicked PA into ring-shaped heptamers (data not shown). The heptamers can be detected as a low mobility species when the mixture is electrophoresed on a nondenaturing polyacrylamide gel (Fig. 2A, compare lane 3 to lanes 1 and 2). Heptamers were formed when LFN was mixed
with nicked PA486EA, PA522TI, and PA592RA (Fig. 2A, lanes 7, 15, and 17). No low-mobility species was observed, however, when
LFN was mixed with nicked PA483QA, PA512DA, or PA514LA (Fig. 2A, lanes 5, 9, and 11). A reduced amount of the low mobility band was observed with PA520DA (Fig. 2A, lane 13).
|
Rubidium release mediated by PA mutants.
On the
two-dimensional surface of cells, trypsin-nicked PA self-associates
into oligomers which, when exposed to low-pH buffer, form
cation-selective channels through the membrane. We loaded cells with
86Rb and tested whether they released it when exposed to
wild-type or mutant PA (Fig. 3).
Mutations at amino acids 483, 486, 514, 520, 522, and 592 of PA had no
significant effect on channel formation. PA512DA, which did not form
oligomers on native gels or on a monoQ column, was almost completely
defective at releasing 86Rb.
|
Translocation of LFN by PA mutants.
Channel
formation is thought to be necessary for translocation of the enzymic
moieties of anthrax toxin, but it is unclear whether the two processes
are distinct and separable. To investigate whether the mutations
affected the ability of PA to translocate LFN across a cell
membrane, we first incubated trypsin-nicked PA with CHO-K1 cells at
4°C so that it would oligomerize and remain on the cell surface.
LFN labeled with 35S was bound to the
oligomers, and a low-pH buffer was added to induce translocation. The
translocation efficiency can be determined by dividing the amount of
LFN that is protected from extracellularly added
protease by the amount of LFN bound by cells. The PA
mutants all bound similar amounts of LFN, except for
PA514LA (55% compared to wild-type) and PA512DA (28%) (Fig.
4). The translocation efficiencies of
wild-type PA, PA486EA, PA514LA, PA520DA, PA522TI, and PA592RA were similar (69, 77, 70, 66, 70, and 67%, respectively). The translocation efficiencies of PA483QA (32%) and PA512DA (51%) were
lower than that of the wild type.
|
Cytotoxity of PA mutants.
We assessed the activity of the
site-directed PA mutants in a cytotoxicity assay using
LFN-DTA. In this assay, PA and LFN-DTA are
added to CHO-K1 cells and viability is assessed after 4 h by the
cells' ability to incorporate tritiated leucine into proteins. The
concentration of wild-type PA that inhibits leucine incorporation by
50% under the conditions chosen is (10 ± 1.0) × 10
11 M. Similar concentrations of the PA mutants PA483QA
[(11 ± 1) × 10
11 M], PA486EA [(9 ± 2) × 10
11 M], PA522TI [(12 ± 2) × 10
11 M], and PA592RA [(10 ± 4) × 10
11 M] were required to inhibit leucine uptake by 50%.
The concentrations of PA512DA [(38 ± 9) × 10
11 M], PA514LA [(21 ± 6) × 10
11 M], and PA520DA [(16 ± 3) × 10
11 M] required to inhibit leucine uptake were
significantly higher than that of the wild type.
| |
DISCUSSION |
|---|
|
|
|---|
Of the four domains of PA, domain 3 (amino acids 488 to 595) is perhaps the least well understood. We investigated the function of this domain by isolating mutations in it that are detrimental to PA activity. To do so, we introduced random mutations into domain 3 by error-prone PCR and screened for proteins that were defective in mediating killing of CHO-K1 cells by LFN-DTA. The source of PA protein in this assay, lysate derived from PA-expressing E. coli cells that had been infected with and lysed by bacteriophage T7, allowed us to screen a large number of PA mutants without having to purify them individually. We used T7 to lyse cells because it requires fewer manipulations and is more efficient than either osmotic shock or freeze-thawing protocols.
In our first screen, we exposed CHO-K1 cells to mutant PA lysates and an amount of LFN-DTA that killed the cells with wild-type PA. The fact that 38 of the 48 defective clones isolated did not express full-length protein came as a surprise since, at the level of dPTP-induced mutagenesis we used (approximately one mutation per clone), we predicted that only 2% of the mutations would be nonsense mutations. We believe that the majority of truncated proteins we detected had mutations that destabilized the structure of domain 3, making the proteins sensitive to proteases. In the second screen, we distinguished between truncated PA and full-length PA molecules with activity defects by using two concentrations of LFN-DTA. The mutants from both screens were sequenced (Table 1).
We classified the mutants into five groups based on the location of the
mutations in the crystal structure of the PA63 heptamer. The mutants of the first group (Table 1) have mutations in a loop
(amino acids 510 to 518) that inserts into a cleft in domain 1 of the
adjacent monomer (Fig. 5). The cleft
consists of amino acids 192 to 205 (1
12-1
13 hairpin) and amino acids 239 to
249. The 1
12-1
13 hairpin is the region of
PA that moves the most upon oligomerization (18). We made
single alanine mutations at amino acids 512 and 514 in a wild-type
background. Amino acid 512 was chosen after identifying the cluster of
mutations in the 510-to-518 loop, because we thought it might make a
hydrogen bond with an amino acid in the adjacent monomer (this is
unclear because of the low resolution of the heptamer structure).
PA512DA was defective in all of the assays we performed, and we could
not detect the assembly of the heptameric form of this mutant using a
MonoQ column (data not shown). Although the heptameric form of PA514LA
bound LFN, trypsin-nicked PA514LA did not form oligomers on
native gels when mixed with LFN. On cells, nicked PA514LA
bound less LFN than did wild-type PA. This mutant also
showed a defect in the cell killing assay with LFN-DTA.
Nevertheless, PA514LA formed channels in the rubidium release assay,
indicating that the sensitivity of this assay is not sufficient to
detect this mild mutation. These data indicate that the loop comprised
of amino acids 510 to 518, and amino acid 512 in particular, is
important for the oligomerization of PA63.
|
The second group of mutants consists of the domain 2 mutants, PAKC483QH, PAKC485QH, and PAKC486EG. These amino acids are situated at the monomer-monomer interface of the PA63 heptamer (Fig. 5). We introduced single alanine mutations at positions 483 and 486 into a wild-type PA background to assess the importance of these amino acids to PA activity. A high-molecular-weight band was observed when LFN and wild-type nicked PA were electrophoresed together on a native gel but not when LFN and trypsin-nicked PA483QA were. Since this band results from LFN inducing the heptamerization of PA63, this experiment suggested that amino acid 483 is involved in oligomerization. Consistent with this, MonoQ chromatography of nicked PA483QA yielded lower amounts of heptamer than did the wild type (data not shown). Although oligomers presumably form on the cell surface, these oligomers must not be assembled efficiently, because they do not translocate as efficiently as wild-type heptamer. PA486EA behaved like wild-type PA in all of the assays performed, which may be explained by the fact that a Glu-to-Gly mutation was isolated in the screen. The glycine residue might have disrupted the alpha-helix, consisting of amino acids 476 to 487, whereas the alanine mutation might not have. Thus, amino acid 486 of PA probably does not have a direct role in the oligomerization process.
The mutants in the third group have mutations in a pocket on the outer face (opposite the lumen) of the heptamer. We introduced the single mutations 520DA and 522TI into a wild-type background to determine the functional defect in this group. PA522TI showed a wild-type phenotype in all of the assays performed. Trypsin-nicked PA520DA did not form oligomers when mixed with LFN and electrophoresed on native gels; it showed a mild defect in the cell killing assay, but it appeared normal in other assays. This suggests that the mutants in this group are mildly defective in oligomerization. Although these amino acids are not directly involved in monomer-monomer interactions, mutations at these positions might affect the positioning of the nearby loop that consists of amino acids 510 to 518. The mutant background (PA481LV 607AI) that was used in the screen may have enhanced the effect of these mutations.
The fourth group of mutants consists of PAKC592RK, PAKC597HR 496KE, PAKC602ND, and PAKC545KE 602NS. The arginine at position 592, which is in domain 3, may form a hydrogen bond with the asparagine residue at position 602, in domain 4. Amino acid 597 is also in domain 4, close in space to these amino acids. We made an arginine-to-alanine mutation at amino acid 592 and found that it did not affect activity in any of the assays we performed. The original PAKC592RK mutant that we isolated was only mildly defective at killing CHO-K1 cells with the lower concentration of LFN-DTA. The mild defect may have been a result of a lower concentration of PA in the lysate, or the mutation may have rendered the protein less stable. In fact, it has been suggested previously that the region consisting of amino acids 592 to 608 is important for the stability of PA (3).
A number of mutations we isolated were in buried amino acids (491IT, 494NS, 506AV, 542YC, 554FL, and 554FS). These mutations, comprising group 5, probably caused structural rearrangements in the protein, so we did not pursue them further. Even though our screen was not saturating, it is interesting that we did not isolate any single mutations between amino acids 530 and 590 other than mutations in buried amino acids. Although this region of PA is close to regions that are thought to interact with EF, LF, and the receptor, we did not obtain any mutants that were defective in either interaction. In addition, the site-directed mutants PA549EK, PA563KE, and PA568EK did not show activity defects (J. Mogridge, unpublished data).
The results of our screens suggest that domain 3 is important for the heptamerization of PA63. A single mutation at amino acid 512 is sufficient to inhibit oligomerization, as determined by native gel electrophoresis and its reduced ability to form channels on cell membranes. This mutant protein must not be completely defective for oligomerization, however, because it is still able to mediate cell death by LFN-DTA, although concentrations higher than wild-type concentrations are required.
An unexpected result from our examination of PA512DA and PA514LA was that these proteins were also defective in binding LFN on the cell surface. Although it is conceivable that these mutations affect both oligomerization and LFN binding, we think that this result suggests that oligomerization of PA63 is required for LFN binding. This notion would also explain how LFN can stimulate the heptamerization of PA63 from nicked PA, by stabilizing PA63 dimers and lower-order oligomers. It would also explain why LFN binds PA63 heptamers formed from PA514LA but does not bind nicked PA514LA in native gels. Thus, these results suggest that EF and LF stably associate with PA63 only after it has oligomerized.
The screen we devised to isolate mutations in PA that affect its function can be easily adapted to isolate muations in other toxins or other proteins that act at the surface of mammalian cells and induce an observable phenotype. This screen is also ideally suited to the isolation of dominant negative toxin mutants, which may be useful as therapeutic agents.
| |
ACKNOWLEDGMENTS |
|---|
We thank Borden Lacy for advice and for assisting with the figures.
This work was supported by a grant (R37-A122021) from the National Institute of Allergy and Infectious Disease. J.M. was supported in part by a postdoctoral fellowship from the Medical Research Council of Canada. M.M. was supported in part by a postdoctoral fellowship from the Direction des Systèmes de force et de la Prospective (9860830) and by the Philippe Foundation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115. Phone: (617) 432-1930. Fax: (617) 432-0115. E-mail: jcollier{at}hms.harvard.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Benson, E. L., P. D. Huynh, A. Finkelstein, and R. J. Collier. 1998. Identification of residues lining the anthrax protective antigen channel. Biochemistry 37:3941-3948[CrossRef][Medline]. |
| 2. |
Blaustein, R. O.,
T. M. Koehler,
R. J. Collier, and A. Finkelstein.
1989.
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.
Proc. Natl. Acad. Sci. USA
86:2209-2213 |
| 3. |
Brossier, F.,
J. Sirard,
C. Guidi-Rontani,
E. Duflot, and M. Mock.
1999.
Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen.
Infect. Immun.
67:964-967 |
| 4. |
Duesbery, N. S.,
C. P. Webb,
S. H. Leppla,
V. M. Gordon,
K. R. Klimpel,
T. D. Copeland,
N. G. Ahn,
M. K. Oskarsson,
K. Fukasawa,
K. D. Paull, and G. F. V. Woude.
1998.
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.
Science
280:734-737 |
| 5. |
Friedlander, A. M.
1986.
Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.
J. Biol. Chem.
261:7123-7126 |
| 6. |
Gordon, V. M.,
S. H. Leppla, and E. L. Hewlitt.
1988.
Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin.
Infect. Immun.
56:1066-1069 |
| 7. | Gordon, V. M., A. Rehemtulla, and S. H. Leppla. 1997. A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen. Infect. Immun. 65:3370-3375[Abstract]. |
| 8. | Guidi-Rontani, C., M. Weber-Levy, M. Mock, and V. Cabiaux. 2000. Translocation of Bacillus anthracis lethal and oedema factors across endosome membranes. Cell. Microbiol. 2:259-264[CrossRef][Medline]. |
| 9. |
Leppla, S. H.
1982.
Anthrax toxin edema factor: a bacterial adenylate cyclase that increase cAMP concentrations in eukaryotic cells.
Proc. Natl. Acad. Sci. USA
79:3162-3166 |
| 10. | Leppla, S. H. 1995. Anthrax toxins, p. 543-572. In J. Moss, B. Iglewski, M. Vaughan, and A. T. Tu (ed.), Bacterial toxins and virulence factors in disease. Dekker, New York, N.Y. |
| 11. |
Little, S. F.,
J. M. Novak,
J. R. Lowe,
S. H. Leppla,
Y. Singh,
K. R. Klimpel,
B. C. Lidgerding, and A. M. Friedlander.
1996.
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.
Microbiology
142:707-715 |
| 12. | Miller, C. J., J. L. Elliott, and R. J. Collier. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38:10432-10441[CrossRef][Medline]. |
| 13. | Milne, J. C., S. R. Blanke, P. C. Hanna, and R. J. Collier. 1995. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 15:661-666[CrossRef][Medline]. |
| 14. | Milne, J. C., and R. J. Collier. 1993. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:647-653[Medline]. |
| 15. |
Milne, J. C.,
D. Furlong,
P. C. Hanna,
J. S. Wall, and R. J. Collier.
1994.
Anthrax protective antigen forms oligomers during intoxication of mammalian cells.
J. Biol. Chem.
269:20607-20612 |
| 16. |
Molloy, S. S.,
P. A. Bresnahan,
S. H. Leppla,
K. R. Klimpel, and G. Thomas.
1992.
Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen.
J. Biol. Chem.
267:16396-16402 |
| 17. |
Pellizzari, R.,
C. Guidi-Rontani,
G. Vitale,
M. Mock, and C. Montecucco.
1999.
Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LFP/IFN -induced release of NO and TNF .
FEBS Lett.
462:199-204[CrossRef][Medline].
|
| 18. | Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature (London) 385:833-838[CrossRef][Medline]. |
| 19. |
Singh, Y.,
K. R. Klimpel,
C. P. Quinn,
V. K. Chaudhary, and S. H. Leppla.
1991.
The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.
J. Biol. Chem.
266:15493-15497 |
| 20. | Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711[CrossRef][Medline]. |
| 21. | Wesche, J., J. L. Elliott, P. Ø. Falnes, S. Olsnes, and R. J. Collier. 1998. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 37:15737-15746[CrossRef][Medline]. |
| 22. | Zaccolo, M., D. M. Williams, D. M. Brown, and E. Gherardi. 1996. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J. Mol. Biol. 255:589-603[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»